The FTC has challenged biotech Amgen’s proposed $28 billion purchase of rare-disease drugmaker Horizon
, in a rare effort by antitrust enforcers to prevent a merger of pharmaceutical companies.from closing. A federal judge would need to approve the injunction. That is part of a two-step legal process the agency typically uses to prevent mergers it believes are illegal.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Horizon shares sink on report that FTC will sue to block takeover by AmgenShares of Horizon Therapeutics Inc. plunged 15% in extended trading Monday after Bloomberg News reported the FTC is expected to file a lawsuit to block Amgen...
Read more »
FTC to block Amgen's $27.8 billion deal for Horizon Therapeutics - sourceThe U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc's $27.8 billion deal to buy Horizon Therapeutics PLC , a person familiar with the matter told Reuters.
Read more »
Horizon Therapeutics stock plunges on report FTC is preparing to block Amgen dealThe deal is bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Read more »
FTC Poised to Block Amgen’s $27.8 Billion Deal for Horizon TherapeuticsThe Federal Trade Commission is preparing to block Amgen’s $28 billion deal to buy Horizon Therapeutics
Read more »
FTC sues to block Amgen acquisition of Horizon TherapeuticsThe deal was a bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Read more »
FTC sues to block $27.8 billion acquisition of Horizon Therapeutics, which has U.S. headquarters in DeerfieldThe suit marks the first time the FTC has tried to stop a pharmaceutical merger in years
Read more »